Cargando…
The virtual cell based assay: Current status and future perspectives
In order to replace the use of animals in toxicity testing, there is a need to predict in vivo toxic doses from concentrations that cause toxicological effects in relevant in vitro systems. The Virtual Cell Based Assay (VCBA) estimates time-dependent concentration of a test chemical in the cell and...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Pergamon Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5742635/ https://www.ncbi.nlm.nih.gov/pubmed/28108195 http://dx.doi.org/10.1016/j.tiv.2017.01.009 |
_version_ | 1783288414927323136 |
---|---|
author | Graepel, Rabea Lamon, Lara Asturiol, David Berggren, Elisabet Joossens, Elisabeth Paini, Alicia Prieto, Pilar Whelan, Maurice Worth, Andrew |
author_facet | Graepel, Rabea Lamon, Lara Asturiol, David Berggren, Elisabet Joossens, Elisabeth Paini, Alicia Prieto, Pilar Whelan, Maurice Worth, Andrew |
author_sort | Graepel, Rabea |
collection | PubMed |
description | In order to replace the use of animals in toxicity testing, there is a need to predict in vivo toxic doses from concentrations that cause toxicological effects in relevant in vitro systems. The Virtual Cell Based Assay (VCBA) estimates time-dependent concentration of a test chemical in the cell and cell culture for a given in vitro system. The concentrations in the different compartments of the cell and test system are derived from ordinary differential equations, physicochemical parameters of the test chemical and properties of the cell line. The VCBA has been developed for a range of cell lines including BALB/c 3T3 cells, HepG2, HepaRG, lung A459 cells, and cardiomyocytes. The model can be used to design and refine in vitro experiments and extrapolate in vitro effective concentrations to in vivo doses that can be applied in risk assessment. In this paper, we first discuss potential applications of the VCBA: i) design of in vitro High Throughput Screening (HTS) experiments; ii) hazard identification (based on acute systemic toxicity); and iii) risk assessment. Further extension of the VCBA is discussed in the second part, exploring potential application to i) manufactured nanomaterials, ii) additional cell lines and endpoints, and considering iii) other opportunities. |
format | Online Article Text |
id | pubmed-5742635 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Pergamon Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-57426352018-01-02 The virtual cell based assay: Current status and future perspectives Graepel, Rabea Lamon, Lara Asturiol, David Berggren, Elisabet Joossens, Elisabeth Paini, Alicia Prieto, Pilar Whelan, Maurice Worth, Andrew Toxicol In Vitro Article In order to replace the use of animals in toxicity testing, there is a need to predict in vivo toxic doses from concentrations that cause toxicological effects in relevant in vitro systems. The Virtual Cell Based Assay (VCBA) estimates time-dependent concentration of a test chemical in the cell and cell culture for a given in vitro system. The concentrations in the different compartments of the cell and test system are derived from ordinary differential equations, physicochemical parameters of the test chemical and properties of the cell line. The VCBA has been developed for a range of cell lines including BALB/c 3T3 cells, HepG2, HepaRG, lung A459 cells, and cardiomyocytes. The model can be used to design and refine in vitro experiments and extrapolate in vitro effective concentrations to in vivo doses that can be applied in risk assessment. In this paper, we first discuss potential applications of the VCBA: i) design of in vitro High Throughput Screening (HTS) experiments; ii) hazard identification (based on acute systemic toxicity); and iii) risk assessment. Further extension of the VCBA is discussed in the second part, exploring potential application to i) manufactured nanomaterials, ii) additional cell lines and endpoints, and considering iii) other opportunities. Pergamon Press 2017-12 /pmc/articles/PMC5742635/ /pubmed/28108195 http://dx.doi.org/10.1016/j.tiv.2017.01.009 Text en © 2017 The Authors http://creativecommons.org/licenses/by/4.0/ This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Graepel, Rabea Lamon, Lara Asturiol, David Berggren, Elisabet Joossens, Elisabeth Paini, Alicia Prieto, Pilar Whelan, Maurice Worth, Andrew The virtual cell based assay: Current status and future perspectives |
title | The virtual cell based assay: Current status and future perspectives |
title_full | The virtual cell based assay: Current status and future perspectives |
title_fullStr | The virtual cell based assay: Current status and future perspectives |
title_full_unstemmed | The virtual cell based assay: Current status and future perspectives |
title_short | The virtual cell based assay: Current status and future perspectives |
title_sort | virtual cell based assay: current status and future perspectives |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5742635/ https://www.ncbi.nlm.nih.gov/pubmed/28108195 http://dx.doi.org/10.1016/j.tiv.2017.01.009 |
work_keys_str_mv | AT graepelrabea thevirtualcellbasedassaycurrentstatusandfutureperspectives AT lamonlara thevirtualcellbasedassaycurrentstatusandfutureperspectives AT asturioldavid thevirtualcellbasedassaycurrentstatusandfutureperspectives AT berggrenelisabet thevirtualcellbasedassaycurrentstatusandfutureperspectives AT joossenselisabeth thevirtualcellbasedassaycurrentstatusandfutureperspectives AT painialicia thevirtualcellbasedassaycurrentstatusandfutureperspectives AT prietopilar thevirtualcellbasedassaycurrentstatusandfutureperspectives AT whelanmaurice thevirtualcellbasedassaycurrentstatusandfutureperspectives AT worthandrew thevirtualcellbasedassaycurrentstatusandfutureperspectives AT graepelrabea virtualcellbasedassaycurrentstatusandfutureperspectives AT lamonlara virtualcellbasedassaycurrentstatusandfutureperspectives AT asturioldavid virtualcellbasedassaycurrentstatusandfutureperspectives AT berggrenelisabet virtualcellbasedassaycurrentstatusandfutureperspectives AT joossenselisabeth virtualcellbasedassaycurrentstatusandfutureperspectives AT painialicia virtualcellbasedassaycurrentstatusandfutureperspectives AT prietopilar virtualcellbasedassaycurrentstatusandfutureperspectives AT whelanmaurice virtualcellbasedassaycurrentstatusandfutureperspectives AT worthandrew virtualcellbasedassaycurrentstatusandfutureperspectives |